申请人:Hokuriku Pharmaceutical Co., Ltd.
公开号:US05095022A1
公开(公告)日:1992-03-10
A piperidine derivative represented by the following general formula (I): ##STR1## wherein R represents a hydrogen atom or a lower alkyl group; X represents --CH.dbd.CH--, --CH.sub.2 CH.sub.2 --, or --CH.sub.2 O--; Y represents an alkylene group having 1 to 5 carbon atoms which may be optionally substituted with a lower alkyl group, or Y represents an --A--O--B-- group wherein A and B are the same or different and each independently represented an alkylene group having 1 to 3 carbon atoms which may be optionally substituted with a lower alkyl group is disclosed. Also disclosed are a pharmacologically acceptable salt of a compound of formula (I), a method for preparation of a compound of formula (I), an antihistaminic and antiallergic agent comprising a compound of formula (I), a pharmaceutical composition comprising a compound of formula (I), and a method for the treatment of an allergic disease by administering a compound of formula (I).
以下是一种由下列通式(I)表示的哌啶衍生物:##STR1## 其中R代表氢原子或较低的烷基基团;X代表--CH.dbd.CH--,--CH.sub.2 CH.sub.2 --或--CH.sub.2 O--;Y代表具有1到5个碳原子的烷基基团,该基团可以选择性地用较低的烷基基团取代,或者Y代表--A--O--B--基团,其中A和B相同或不同,且每个都独立地表示具有1到3个碳原子的烷基基团,该基团可以选择性地用较低的烷基基团取代。还公开了通式(I)化合物的药理上可接受的盐、一种制备通式(I)化合物的方法、包括通式(I)化合物的抗组胺和抗过敏剂、包括通式(I)化合物的药物组合物,以及通过给予通式(I)化合物治疗过敏疾病的方法。